LEPU Scientech Medical Technology (Shanghai) Co., Ltd. provided unaudited consolidated earnings guidance for the six months ended June 30, 2023. For the period, the company expects to record a net profit attributable to the Shareholders of approximately RMB 73 million, representing an increase of around 200% as compared to the corresponding period last year. It is estimated that the non-IFRS profit is approximately RMB 85 million.

The expected increase in net profit attributable to the Shareholders was mainly due to the followings: the sales volume of the Group's last generation of nitinol occluder products in the Reporting Period increased significantly compared with the corresponding period last year. This growth was driven by the broad market acceptance of these products, enabled by the Group's extensive distributor network, effective academic promotion, and strong marketing capabilities and the Group commenced sales of the MemoSorb full-biodegradable polymer-based occluder systems following the commercialization of this product, which generated an additional revenue stream for the Group in the Reporting Period as compare with the corresponding period last year.